Study of the Indications for Amyloid Positon Emission Tomography (PET) Scans and Their Usefulness for Patients With Suspected Alzheimer's Disease (AD)

Recruiting

• Conditions: Alzheimer Disease

• Registration Number: NCT06467981
• Lead Sponsor: Central Hospital, Nancy, France

Brief Summary

The recent clinical authorization of amyloid Positon Emission Tomography (PET) in France represents a crucial step for the nuclear medicine community involved in the diagnosis of Alzheimer's disease (AD).

Detailed Description

The recent clinical authorization of amyloid Positon Emission Tomography (PET) in France represents a crucial step for the nuclear medicine community involved in the diagnosis of Alzheimer's disease (AD). At the era of Amyloid, Tau, Neurodegeneration (ATN) biomarkers, amyloid PET fills a need in patients with an atypical or mixed clinical presentation, in particular young patients (\< 65 years old), when the lumbar puncture is contraindicated or not feasible for technical reasons. Importantly, a negative amyloid PET scan discards the diagnosis of AD. Furthermore, early phase imaging of amyloid PET allows to estimate the perfusion neuronal state, increasing the diagnostic value of such PET radiotracer. Its role could be further developed in routine care for the selection and monitoring of promising disease modifiers therapies.

Study Timeline

• Study First Submitted: 2024-06-11
• Study First Submitted QC: 2024-06-18
• Study First Posted: 2024-06-21
• Status Verified: 2024-09
• Study Start: 2024-11-01
• Primary Completion: 2024-12-30
• Last Update Submitted: 2025-02-11
• Last Update Posted: 2025-02-13
• Study Completion: 2025-02-15

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 160

Inclusion Criteria

• Patients aged = or > 18 years
• Patients who have had an amyloid PET scan with a PET request form including the indications for the examination
• Patient informed via a newsletter and non-opposition to the use of their data for research purposes (research objectives clearly explained in the letters)

Exclusion Criteria

• Patient opposition to the use of their data for this research

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluate the indications for Amyloid PET in 7 centers in France to assess the relevance of the examination	1 day	Correlation between the request and the recommendations

Secondary Outcome Measures

Name	Time	Method
Evaluate the frequency of positive examinations for the diagnosis of AD	1 day	Number of positive PET exam

Trial Locations

Locations (1)

Nuclear medicine department; 🇫🇷 Vandoeuvre/les/Nancy, France